Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 15/20 | 0.70 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.47 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3268138 | 0.91 | FAAH (0.78) | FAAHSMN1; SMN2ALDH1A1 | |
| SCHEMBL3275295 | 0.86 | FAAH (0.83) | FAAHLOXL2 | |
| SCHEMBL3442148 | 0.85 | FAAH (0.71) | FAAHSLC6A7KDM4EALDH1A1 | |
| SCHEMBL3269809 | 0.84 | FAAH (0.69) | FAAH | |
| SCHEMBL3268847 | 0.83 | FAAH (0.68) | FAAHSLC6A7KDM4EALDH1A1 | |
| SCHEMBL3270497 | 0.82 | FAAH (1.00) | FAAHKDM4EALDH1A1 | |
| SCHEMBL13294922 | 0.82 | FAAH (0.49) | FAAH | |
| SCHEMBL3275071 | 0.81 | FAAH (0.57) | FAAHHRH4NPC1TSHRRECQL | |
| SCHEMBL3269553 | 0.81 | FAAH (0.60) | FAAHSLC6A7 | |
| SCHEMBL3268636 | 0.80 | FAAH (0.78) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| US-20100234389-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-16 | — | — | US | disclosed |
| EP-2199282-A1 | AMIDE COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2010-06-23 | — | — | EP | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
| US-20090163508-A1 | AMIDE COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234389-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885HRH4 24/4885NPC1 2637/4885 |
| US-20090163508-A1 | AMIDE COMPOUND | FAAH, FAAH2, NAAA | FAAH 1/4885HRH4 24/4885NPC1 2637/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.